13/07/2026 Novartis received Health Canada approval for VANRAFIA™ to reduce proteinuria in adults with primary IgAN IQIRVO® demonstrated statistically significant improvement in ALP normalization in patients with PBC in Phase 3b study Q32 Bio announced results from Part B of the Phase 2a study of bempikibart in Alopecia Areata Novartis received Health Canada approval for VANRAFIA™ to reduce proteinuria in adults with primary IgAN (Ref) Novartis Pharmaceuticals Canada announce

01/07/2026 Ostuka reported positive Phase 3 results for sibeprenlimab in IgAN Ostuka reported positive Phase 3 results for sibeprenlimab in IgAN (Ref) Otsuka Pharmaceutical announced positive topline full study results from the Phase 3, VISIONARY/ NCT05248646 trial for VOYXACT® (sibeprenlimab-szsi; Anti-APRIL) in adults with primary IgA nephropathy (IgAN) at risk of disease progression. Sibeprenlimab demonstrated statistically significant stabilization of eGFR with evidence

15/06/2026 SynAct Pharma reported Phase 2b data of resomelagon in Rheumatoid Arthritis Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy XBiotech launched Phase 2 trial evaluating vilamakitug for the treatment of active axial spondyloarthritis Spyre announced Part A results from Phase 2 trial of SPY002 in moderate-to-severe UC SynAct Pharma reported Phase 2b data of resomelagon in Rheumatoid Arthritis (Ref) SynAct Pharma AB

08/06/2026 Telitacicept received NMPA conditional approval for the treatment of IgA Nephropathy in China Telitacicept received NMPA approval for the treatment of Sjögren’s disease in China Alvotech announced FDA acceptance of a BLA for AVT16, a proposed interchangeable biosimilar to Entyvio® Telitacicept received NMPA conditional approval for the treatment of IgA Nephropathy in China (Ref) Vor Bio and RemeGen Co. announced that China’s National Medicinal Products Administrati

05/06/2026 Otsuka presented interim Phase 3 data showing sibeprenlimab preserved kidney function over 12 months in IgAN InnoCare presented Phase 2b results for Orelabrutinib in patients with SLE at EULAR-2026 Otsuka presented interim Phase 3 data showing sibeprenlimab preserved kidney function over 12 months in IgAN (Ref) Otsuka Pharmaceutical announced that VOYXACT® (sibeprenlimab-szsi; APRIL inhibitor) preserved kidney function compared to placebo over 12 months in adults w

02/06/2026 Gilead announced positive phase 3 results for Seladelpar in PBC Vera Therapeutics announced US FDA alignment on an earlier ORIGIN phase 3 eGFR analysis to support potential full approval for atacicept in adults with IgA Nephropathy Rise Therapeutics announced completion of enrollment in the 4-Week dose expansion cohort for R-2487 in RA clinical trial Gilead announced positive phase 3 results for Seladelpar in PBC (Ref) Gilead Sciences announced positive results fro

01/06/2026 Vertex announced US FDA acceptance of BLA for accelerated approval of Povetacicept in IgA nephropathy Abivax announced Phase 3 maintenance results for obefazimod in moderately to severely active UC Vertex announced US FDA acceptance of BLA for accelerated approval of Povetacicept in IgA nephropathy (Ref) Vertex Pharmaceuticals announced that the US FDA had accepted its Biologics License Application (BLA) submission for povetacicept (anti-BAFF and APRIL) in adults w

26/05/2026 Jade Biosciences announced first participant dosed in Phase 2 trial of JADE101 in IgA Nephropathy Jade Biosciences announced first participant dosed in Phase 1 trial of JADE201 in Rheumatoid Arthritis Jade Biosciences announced first participant dosed in Phase 2 trial of JADE101 in IgA Nephropathy (Ref) Jade Biosciences announced that the first participant had been dosed in the Phase 2, JUNIPER/ NCT07541287, trial which evaluated JADE101(Anti-APRIL) in participants

21/04/2026 FDA accepted application for Roche’s Gazyva for the treatment of SLE Cristcot announced FDA acceptance of NDA for ngHCA for treatment of UC of the Rectum AstraZeneca announced Phase 3 results for ravulizumab for IgA Nephropathy FDA accepted application for Roche’s Gazyva for the treatment of SLE ( Ref ) Roche announced that the US FDA had accepted a supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab; anti-CD20) for the treatment o

09/03/2026 Pfizer announced Phase 2 results of tilrekimig in AD Vertex announced Phase 3 results of Povetacicept in IgA Nephropathy Pfizer announced Phase 2 results of tilrekimig in AD ( Ref ) Pfizer announced positive topline results from its Phase 2 study that evaluated tilrekimig (PF-07275315; trispecific antibody targets Il-4, IL-13 and TSLP) for the treatment of adult patients with moderate to severe atopic dermatitis (AD) The study met its primary endpoint, demonstratin

13/02/2026 Novartis announced Phase 3 data in adult patients with IgA nephropathy Novartis announced Phase 3 data in adult patients with IgA nephropathy ( Ref ) Novartis announced final results from its Phase 3 ALIGN/ NCT04573478 study which evaluated Vanrafia (atrasentan; an ETA receptor antagonist) in adult patients with IgA nephropathy (IgAN) The study demonstrated a slowing of kidney function decline in adult patients with IgAN The ALIGN study showed a difference of 2.39